Acute chest syndrome in the setting of SARS-COV-2 infections-A case series at an urban medical center in the Bronx

Pediatr Blood Cancer. 2020 Nov;67(11):e28579. doi: 10.1002/pbc.28579. Epub 2020 Sep 7.

Abstract

New York City has emerged as one of the epicenters of the SARS-COV-2 pandemic, with the Bronx being disproportionately affected. This novel coronavirus has caused significant respiratory manifestations raising the concern for development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD). We report a series of pediatric SCD SARS-COV-2-positive patients admitted with ACS. SARS-COV-2-positive SCD patients, who did not develop ACS, were the comparison group. Hydroxyurea use (P-value = .02) and lower absolute monocyte counts (P-value = .04) were noted in patients who did not develop ACS. These preliminary findings need to be further evaluated in larger cohorts.

Keywords: COVID-19; hemoglobinopathies; infections in immunocompromised hosts; sickle cell disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Chest Syndrome / complications*
  • Acute Chest Syndrome / diagnosis
  • Acute Chest Syndrome / drug therapy
  • Adolescent
  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / drug therapy
  • Anti-Bacterial Agents / therapeutic use
  • Antisickling Agents / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / diagnosis
  • COVID-19 Drug Treatment
  • COVID-19 Testing
  • Child
  • Doxycycline / therapeutic use
  • Female
  • Hospitals, Urban
  • Humans
  • Hydroxyurea / therapeutic use
  • Male
  • New York City
  • Polymerase Chain Reaction
  • SARS-CoV-2
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Antisickling Agents
  • Doxycycline
  • Hydroxyurea